## <u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: DALLY Robert Dean Group Art Unit: 1624

Serial No.: 10/599,129 Examiner: Douglas M. WILLIS

Application Date: April 8, 2005 Conf No.: 4638

US Nat'l Entry

Date (if applicable): September 20, 2006

For: PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS

Docket No.: X-17115

## **COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the following comments on the Statement of Reasons for Allowance be entered in the file for the application identified above. Applicants do not believe that any fees are incurred; however, any fees associated with this paper may be charged to Eli Lilly Deposit Account No. 05-0840.

Applicants agree with Examiner concerning Reasons for Allowance: "The prior art is silent with regard to pyrrolidines substituted with R<sup>1</sup>, as recited in Claim 2. Consequently, the limitation on the core of the substituted pyrrolidines of the formula I(a) that is not taught or fairly suggested in the prior art is R<sup>1</sup> on the periphery of the pyrrolidine core." Allowance Notice, dated June 03, 2009, page 5. Previously in a telephone interview on May 14, 2009, Applicants acknowledged their continuing duty to the United States Patent and Trademark Office wherein upon allowance of the claims in the present application to provide a copy of the claims to the Examiner in the co-pending application, 10/599,125, and to fully address the outstanding issues in that case, as necessary.

Respectfully submitted,

/Elizabeth A. Dingess-Hammond/

Elizabeth A. Dingess-Hammond Agent for Applicants Registration No. 63,996 Phone: 317-433-3689

Eli Lilly and Company Patent Division/ P.O. Box 6288 Indianapolis, Indiana 46206-6288

July 31, 2009